3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
4
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Colonic Neoplasms
1
Brain Neoplasms
1
Interventions
Trastuzumab
18
Radiosurgery
15
Capecitabine
13
Lapatinib
11
Radiotherapy
9
Magnetic Resonance Spectroscopy
9
trastuzumab deruxtecan
7
Temozolomide
6
tucatinib
4
pembrolizumab
4
paclitaxel-Angiopep-2 conjugate
4
eribulin
4
Vinorelbine
4
Specimen Handling
4
Paclitaxel
4
Methotrexate
4
Cisplatin
4
sacituzumab govitecan
3
pyrotinib
3
abemaciclib
3
Radiation
3
Fluorodeoxyglucose F18
3
pertuzumab
2
palbociclib
2
neratinib
2
durvalumab
2
cediranib
2
cabazitaxel
2
Sodium Chloride
2
Observation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
Doxycycline
×
Breast
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn